The IBTK Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population with disrupted IBTK alleles in the SK-HEP-1 human hepatic adenocarcinoma line. This loss-of-function model supports rigorous dissection of IBTK-mediated regulatory pathways in a liver cancer context. Generated by transient CRISPR reagent delivery, the heterogeneous knockout pool obviates clonal selection and provides a functional knockout background for gene-function studies.
SK-HEP-1 cells were established from ascitic fluid of a liver adenocarcinoma patient and exhibit adherent epithelial-like growth with mixed endothelial properties. The line recapitulates hepatocyte features including bile canaliculus formation, making it a widely accepted model for hepatocellular carcinoma and hepatic signaling research. This genetic background offers a physiologically relevant setting for investigating IBTK??s roles in malignancy-associated processes.
IBTK encodes a negative regulator of BTK, binding and inhibiting BTK enzymatic activity to downmodulate B-cell receptor-initiated cascades. Loss of IBTK relieves suppression of BTK, enhancing phosphorylation of PLC??2, elevating calcium mobilization and NF-??B activation, and altering caspase-3/7-mediated apoptosis. Upstream, IBTK expression is controlled by BCR activation and transcription factors PAX5 and EBF1. The signaling module includes BCR, SYK, BTK, BLNK, PLC??2, IP3, Ca2?, NFAT, and NF-??B, with potential cross-talk involving additional Tec kinases.
Although IBTK is canonically characterized in B-lineage cells, its expression in SK-HEP-1 enables exploration of non-hematopoietic functions, particularly in hepatocellular carcinoma. The knockout model facilitates analysis of IBTK-dependent crosstalk with the PI3K/AKT/mTOR axis and NF-??B signaling in the context of liver tumorigenesis. Researchers can interrogate how IBTK loss impacts proliferation, apoptosis resistance, and drug sensitivity in hepatocyte-derived cancer cells.
Key applications include target validation for B-cell disorders in a cross-lineage system, study of IBTK function in liver cancer biology, and investigation of apoptosis/proliferation regulation. Compatible assays encompass Western blot, phospho-BTK flow cytometry, intracellular calcium flux measurement, Annexin V and BrdU assays, RT-qPCR, co-immunoprecipitation, and NF-??B luciferase reporters. For further information, please contact Ascent Research.
